Helse Bergen HF

Az itteni vizsgálatok

Miről szól a helyszín 154 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Gyermekkori daganatok18 vizsgálat
• Tüdőrák13 vizsgálat
• Akut mieloid leukémia (AML)12 vizsgálat
• Vastagbélrák8 vizsgálat
• Mielodiszplasztikus szindróma (MDS)7 vizsgálat
• Mielóma multiplex6 vizsgálat
• Fabry-betegség5 vizsgálat
• Fej-nyaki daganatok5 vizsgálat
• Migrén5 vizsgálat
• Sclerosis multiplex (SM)5 vizsgálat
• Idiopátiás tüdőfibrózis4 vizsgálat
• Immune thrombocytopenia (ITP)4 vizsgálat
• és még 52

Fázis

• 3. fázis93 vizsgálat
• 2. fázis34 vizsgálat
• 2/3. fázis8 vizsgálat
• 4. fázis8 vizsgálat
• 1/2. fázis7 vizsgálat
• 1. fázis2 vizsgálat

Állapot

• Toboroz63 vizsgálat
• Fut, nem toboroz47 vizsgálat
• Lezárult36 vizsgálat
• Még nem toboroz8 vizsgálat

Fő szponzor

• Takeda7 vizsgálat
• Merck Sharp & Dohme LLC6 vizsgálat
• Boehringer Ingelheim4 vizsgálat
• GlaxoSmithKline4 vizsgálat
• Haukeland University Hospital4 vizsgálat
• és még 94

Futó vizsgálatok

• Még nem toboroz

  Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism

  NCT07816978· 4. fázis· Sahlgrenska University Hospital· Forrás

• Toboroz

  Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET)

  2025-521330-29-00· 2. fázis· Ostfold Hospital Trust· Forrás

• Toboroz

  A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

  NCT01491815· 4. fázis· Karolinska Institutet· Forrás

• Toboroz

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás

• Toboroz

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· 3. fázis· Charite University, Berlin, Germany· Forrás

• Toboroz

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· 3. fázis· AstraZeneca· Forrás

• Még nem toboroz

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· 2. fázis· Oslo Universitetssykehus HF· Forrás

• Toboroz

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· 3. fázis· Boehringer Ingelheim· Forrás

• Toboroz

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· 3. fázis· OncoZenge AB· Forrás

• Még nem toboroz

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· 3. fázis· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Forrás

• Toboroz

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· 3. fázis· Takeda· Forrás

• Toboroz

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás

• Toboroz

  Vididencel in CML-CP Patients With MRD

  NCT07651878· 1. fázis· Mendus· Forrás

• Toboroz

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· 3. fázis· Genmab A/S· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· 3. fázis· Genmab· Forrás

• Toboroz

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· 3. fázis· Incyte Corporation· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• Toboroz

  A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis

  2024-513927-18-00· 2. fázis· Oslo University Hospital HF· Forrás

• Toboroz

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· 3. fázis· Eli Lilly and Company· Forrás

• Még nem toboroz

  IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

  2025-521908-22-00· 2/3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás

• Fut, nem toboroz

  Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

  NCT07220642· 3. fázis· Novo Nordisk A/S· Forrás

• Toboroz

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás

• Toboroz

  A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

  NCT06721013· 1/2. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

  NCT06328608· 2/3. fázis· Chiesi Farmaceutici S.p.A.· Forrás

• Toboroz

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· 3. fázis· Takeda· Forrás

• Toboroz

  Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study

  2023-505573-32-00· 3. fázis· Ostfold Hospital Trust· Forrás

• Fut, nem toboroz

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· 2. fázis· Calluna Pharma AS· Forrás

• Toboroz

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· 3. fázis· GlaxoSmithKline· Forrás

• Toboroz

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· 3. fázis· University Of Cologne· Forrás

• Toboroz

  Plasma cell targeting in ME/CFS

  2024-520094-13-00· 2. fázis· Helse Bergen HF· Forrás

• Toboroz

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· 3. fázis· Daiichi Sankyo Inc.· Forrás

• Toboroz

  The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig)

  2024-517981-40-00· 3. fázis· Oslo University Hospital HF· Forrás

• Toboroz

  Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7

  2023-508196-36-00· 2. fázis· Karolinska University Hospital· Forrás

• Toboroz

  Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer

  2022-502221-18-00· 4. fázis· Aarhus University· Forrás

• Toboroz

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• Toboroz

  eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)

  2023-506289-29-00· 4. fázis· Vestfold Hospital Trust· Forrás

• Toboroz

  Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

  NCT06641414· 3. fázis· Ascentage Pharma Group Inc.· Forrás

• Toboroz

  Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)

  2023-506998-35-00· 3. fázis· Vaestra Goetalandsregionen· Forrás

• Toboroz

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· 3. fázis· Takeda· Forrás

• Toboroz

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· 3. fázis· Uppsala University· Forrás

• Toboroz

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· 3. fázis· GlaxoSmithKline· Forrás

• Fut, nem toboroz

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· 3. fázis· Daiichi Sankyo· Forrás

• Toboroz

  NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

  NCT06651151· 2. fázis· Oslo University Hospital· Forrás

• Fut, nem toboroz

  LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

  NCT02205762· 2/3. fázis· St. Anna Childrens Cancer Research Institute GmbH· Forrás

• Fut, nem toboroz

  DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

  NCT04392504· 1/2. fázis· Oslo University Hospital Hf· Forrás

• Fut, nem toboroz

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás

• Fut, nem toboroz

  Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial

  NCT05029050· 4. fázis· Oslo University Hospital HF· Forrás

• Fut, nem toboroz

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· 3. fázis· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Forrás

Showing 50 of 118.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok15 toboroz
• Akut mieloid leukémia (AML)8 toboroz
• Tüdőrák5 toboroz
• Mielodiszplasztikus szindróma (MDS)4 toboroz
• Akut limfoid leukémia (ALL)3 toboroz
• Migrén3 toboroz
• Fej-nyaki daganatok2 toboroz
• Glioblasztóma2 toboroz
• Hólyagrák2 toboroz
• Immune thrombocytopenia (ITP)2 toboroz
• Krónikus vesebetegség2 toboroz
• Máj- és epeúti rák2 toboroz
• Melanóma2 toboroz
• Petefészekrák2 toboroz
• Sclerosis multiplex (SM)2 toboroz
• Szarkóma2 toboroz
• Vastagbélrák2 toboroz
• 1-es típusú cukorbetegség1 toboroz
• Amiotrófiás laterálszklerózis (ALS)1 toboroz
• Crohn-betegség1 toboroz
• Deep vein thrombosis and pulmonary embolism1 toboroz
• Depresszió1 toboroz
• Elhízás1 toboroz
• Fabry-betegség1 toboroz
• Follikuláris limfóma1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hearing loss1 toboroz
• IgA-nefropátia1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Krónikus mieloid leukémia (CML)1 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)1 toboroz
• Long COVID és ME/CFS1 toboroz
• Lupus (SLE)1 toboroz
• Méhtestrák1 toboroz
• Neuroblasztóma1 toboroz
• Neuroendokrin daganatok1 toboroz
• Pajzsmirigyrák1 toboroz
• Pitvarfibrilláció1 toboroz
• Rheumatoid arthritis1 toboroz
• Sarcoidosis1 toboroz
• Stroke (szélütés)1 toboroz
• Testicular cancer1 toboroz

Lezárt vizsgálatok

• Toboroz

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· 3. fázis· Takeda· Forrás

• Toboroz

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer

  2024-515884-69-00· 3. fázis· Gilead Sciences Inc.· Forrás

• Toboroz

  A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· 3. fázis· Takeda· Forrás

• Lezárult

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· 2. fázis· Novo Nordisk A/S· Forrás

• Fut, nem toboroz

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· 3. fázis· Glaxosmithkline Research & Development Limited· Forrás

• Lezárult

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· 2. fázis· Boehringer Ingelheim International GmbH· Forrás

• Lezárult

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· 2. fázis· Boehringer Ingelheim· Forrás

• Lezárult

  A Study of TAK-861 for the Treatment of Narcolepsy Type 1

  NCT06470828· 3. fázis· Takeda· Forrás

• Fut, nem toboroz

  A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

  NCT06298552· 3. fázis· argenx· Forrás

• Lezárult

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· 3. fázis· Celgene International II S.a.r.l.· Forrás

• Fut, nem toboroz

  A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

  NCT06282159· 2. fázis· Dianthus Therapeutics· Forrás

• Lezárult

  The TAF-MS study

  2023-503814-62-00· 2. fázis· Helse Bergen HF· Forrás

• Fut, nem toboroz

  A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

  NCT05970172· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás

• Lezárult

  Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer

  NCT05724602· 2. fázis· European Organisation For Research And Treatment Of Cancer· Forrás

• Lezárult

  An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)

  2022-501850-12-00· 2. fázis· Arctic Bioscience AS· Forrás

• Lezárult

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· 2. fázis· PTC Therapeutics Inc.· Forrás

• Lezárult

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· 3. fázis· Bayer· Forrás

• Lezárult

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· 4. fázis· H. Lundbeck A/S· Forrás

• Lezárult

  Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

  NCT05162768· 3. fázis· Stealth BioTherapeutics Inc.· Forrás

• Lezárult

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

  NCT05144841· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes

  NCT05168202· 1. fázis· Celgene Corp.· Forrás

• Lezárult

  AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

  NCT05035277· 3. fázis· Oslo University Hospital· Forrás

• Lezárult

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment

  NCT05868135· St. Olavs Hospital· Forrás

• Lezárult

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· 3. fázis· Sanofi· Forrás

• Lezárult

  Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

  NCT04069897· 3. fázis· St. Olavs Hospital· Forrás

• Lezárult

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· 3. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC

  NCT03924869· 3. fázis· Merck Sharp & Dohme Corp.· Forrás

• Lezárult

  A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

  NCT03737214· 3. fázis· Idorsia Pharmaceuticals Ltd.· Forrás

• Lezárult

  Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

  NCT03614234· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás

• Fut, nem toboroz

  A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318· 3. fázis· AbbVie· Forrás

• Lezárult

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· 3. fázis· Klinikum der Universitaet Muenchen AöR· Forrás

• Lezárult

  HD21

  NCT02661503· 3. fázis· University Of Cologne· Forrás